Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Sanofi’s iBGStar blood glucose monitor. ProUroCare’s prostate imaging system. Edwards Lifesciences’ ThruPort IntraClude intra-aortic occlusion device. More new products.

You may also be interested in...



New Products In Brief

Recent product approvals and launches include St. Jude’s Assura and Ellipse ICDs, Boston Scientific’s Ingenio pacemakers and Medtronic’s Valiant Captivia thoracic stent graft system.

Mobile Health In Brief

News from the mobile health industry includes FDA clearance of the first glucose meter that connects to an iPhone.

Quick Listen: Scrip's Five Must-Know Things

 In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.

Table

View full table

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

FDA Leaves Global Harmonization Working Party, Will Focus International Harmonization Efforts Elsewhere

Solventum: The Identity Of 3M’s Health Care Spin-Off

Execs On The Move: October 2023

El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices

See All
UsernamePublicRestriction

Register

MT031202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By